Clinical implications of the use of SGLT2 inhibitors in the management of heart failure

Abstract

Objective: To evaluate the clinical implications of the use of SGLT2 inhibitors in the management of heart failure. Methods: An Integrative Review was carried out using the PubMed database platform, with the aim of locating relevant sources. The search was carried out using the MeSH terms "Sodium-Glucose Transporter 2 Inhibitors", "Heart Failure", in association with the use of the Boolean term "AND" to search for articles, resulting in 985 initial articles. Within these numbers, due to the inclusion and exclusion criteria, only 21 were selected for analysis. Results: The use of SGLT2 inhibitor drugs, have a high level of safety and tolerability in patients with HF and have been shown to prevent the clinical deteriorations inherent in the clinical picture of a patient with HF, as well as promoting improved cardiovascular outcomes regardless of diabetes status, reducing death from all causes, reducing first hospitalization for HF, as well as adverse renal outcomes. Final considerations: SGLT2 inhibitors are beneficial in patients with heart failure and reduced ejection fraction, even in the absence of diabetes.  They are therefore recommended by the guidelines as an additional therapy to standard treatments for heart failure.